{"id":"W4405043889","doi":"10.1182/blood-2024-199542","title":"Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital; University of Calgary; Princess Margaret Cancer Centre","funders":"Juno Therapeutics; Genentech; City of Hope; Pharmacyclics; Gilead Sciences; Kite Pharma; Regeneron Pharmaceuticals; University of Pennsylvania; Bristol-Myers Squibb; AstraZeneca; Celgene; Amgen","keywords":"Medicine; Multiple myeloma; Pomalidomide; Regimen; Lenalidomide; Oncology; Internal medicine; Refractory (planetary science); Phases of clinical research; Clinical trial; Intensive care medicine; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001144884,0.000325528,0.0009565213,0.0002824218,0.000153361,0.0006645904,0.0003306211,0.0002790162,0.0007740433],"category_scores_gemma":[0.001022243,0.0001824075,0.0006761621,0.0004621029,0.0001645715,0.0004442286,0.0001855073,0.00087785,0.0001740609],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005581949,"about_ca_system_score_gemma":0.0005378849,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009247384,"about_ca_topic_score_gemma":0.00389845,"domain_scores_codex":[0.9996699,0.00012366,0.00003526596,0.00005062051,0.00007673613,0.00004384076],"domain_scores_gemma":[0.9994516,0.0001354918,0.0002090325,0.00003653337,0.00006235813,0.000105092],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.08203734,0.00292941,0.1067316,0.001538797,0.003222882,0.0003755148,0.0003074802,0.003675248,0.08248888,0.0002684582,0.006720661,0.7097037],"study_design_scores_gemma":[0.06657625,0.1888718,0.6386215,0.0005589505,0.006449968,0.004210199,0.0002791012,0.007140021,0.03346806,0.0008056161,0.05291309,0.000105446],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9720518,0.02182591,0.001059397,0.0005824239,0.00005497337,0.0004549499,0.001078563,0.00008579453,0.002806239],"genre_scores_gemma":[0.9894485,0.006005765,0.00138777,0.0005849731,0.00005763283,0.000192824,0.001739306,0.00001717072,0.0005659316],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001144884,"threshold_uncertainty_score":0.006054819,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0287834125894258,"score_gpt":0.3350266829619709,"score_spread":0.3062432703725451,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}